Stock comparison
LeMaitre Vascular
Pharming Group N.V.
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
LMAT
LeMaitre Vascular
Market cap
$2.23B
Sector
Healthcare
PHAR
Pharming Group N.V.
Market cap
$889.88M
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | LMAT | PHAR | Winner |
|---|---|---|---|
| Warren Buffett | 77B | 37D | LMAT |
| Benjamin Graham | 89A | 67D | LMAT |
| Philip Fisher | 81C | 43D | LMAT |
| Peter Lynch | 67B | 25F | LMAT |
| Joel Greenblatt | 56D | 44D | LMAT |
| Charlie Munger | 68D | 34F | LMAT |
| Terry Smith | 69D | 41D | LMAT |
Side-by-side metrics
| Metric | LMAT | PHAR |
|---|---|---|
| Market cap | $2.23B | $889.88M |
| P/E (TTM) | 37.1x | 77.6x |
| EV/EBIT | 36.6x | 50.7x |
| ROIC (TTM) | 9.43% | 3.76% |
| Gross margin | 72.39% | 88.12% |
| Net margin | 24.35% | 3.37% |
| Revenue CAGR 5y | 12.75% | 17.35% |
| EPS CAGR 5y | 19.04% | -33.13% |
| Debt / Equity | 0.5x | 0.4x |
| Dividend yield | 0.84% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
LMAT leads on
- EPS CAGR 5y19.04%vs -33.13%+157%
- Dividend yield0.84%vs 0.0%+100%
- Net margin24.35%vs 3.37%+86%
- Market cap$2.23Bvs $889.88M+60%
PHAR leads on
- Revenue CAGR 5y17.35%vs 12.75%+27%
- Gross margin88.12%vs 72.39%+18%
- Debt / Equity0.4xvs 0.5x+7%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.